Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» July 2010
July 2010
Is Johnson & Johnson Really a Safety Stock?
Is Johnson & Johnson Really a Safety Stock?
Seeking Alpha
JNJ
GSK
Novartis
Sanofi
AstraZeneca
Merck declares 38-cent regular quarter dividend
Merck declares 38-cent regular quarter dividend
Yahoo/AP
Merck
dividends
Merck Paid 3,468 Death Claims to Resolve Vioxx Suits
Merck Paid 3,468 Death Claims to Resolve Vioxx Suits
Bloomberg
Merck
settlements
Vioxx
Dynavax starts universal flu vaccine test
Dynavax starts universal flu vaccine test
Bizjournals.com
Dynavax
Flu
vaccines
Better Buy: Cell Therapeutics or Sequenom?
Better Buy: Cell Therapeutics or Sequenom?
Motley Fool
Sequenom
Cell Therapeutics
Drug Company as Masochist: Bristol-Myers Takes Needless Whipping for HIV Drug Prices
Drug Company as Masochist: Bristol-Myers Takes Needless Whipping for HIV Drug Prices
BNET Pharma
HIV
drug pricing
Bristol-Myers Squibb
Antigenics posts positive herpes drug study data
Antigenics posts positive herpes drug study data
Yahoo/AP
Antigenics
genital herpes
herpes simplex 2
Cephalon second-quarter profit rises to $89 mln
Cephalon second-quarter profit rises to $89 mln
Marketwatch
Cephalon
earnings
What Investors Think About Alexza Pharmaceuticals
What Investors Think About Alexza Pharmaceuticals
Motley Fool
Alexza
Genzyme Could Go To $80, Says Analyst
Genzyme Could Go To $80, Says Analyst
CNBC
Genzyme
M&A
Sanofi
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »